menu search

CRSP / Why CRISPR Therapeutics Stock Charged Northward This Week

Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week after a panel of experts potentially set the stage for the first CRISPR/Cas9-based therapy to hit the market next year. Read More
Posted: Nov 3 2023, 09:56
Author Name: The Motley Fool
Views: 100975

CRSP News  

Why CRISPR Therapeutics Stock Charged Northward This Week

By The Motley Fool
November 3, 2023

Why CRISPR Therapeutics Stock Charged Northward This Week

Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week af more_horizontal

CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors

By Zacks Investment Research
November 2, 2023

CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recentl more_horizontal

CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?

By Zacks Investment Research
November 2, 2023

CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings est more_horizontal

Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

By NYTimes
October 31, 2023

Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-ed more_horizontal

FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia

By Barrons
October 31, 2023

FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia

Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease. more_horizontal

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision

By InvestorPlace
October 31, 2023

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision

Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: C more_horizontal

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy

By InvestorPlace
October 27, 2023

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy

Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory deci more_horizontal

2 Fantastic Growth Stocks to Buy Hand Over Fist

By The Motley Fool
October 26, 2023

2 Fantastic Growth Stocks to Buy Hand Over Fist

CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be rea more_horizontal


Search within

Pages Search Results: